Ras-Superfamily GTP-ases in Ovarian Cancer

Cancer Treatment and Research

Volumn 149, Issue , 2009, Pages 229-240

  Cheng, Kwai Wa ^a   Agarwal, Roshan ^a   Mills, Gordon B ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPTOR PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; GUANOSINE TRIPHOSPHATASE; ONCOPROTEIN; RAB PROTEIN; RAS PROTEIN; RHO FACTOR;

CARCINOGENESIS; ENZYME ACTIVATION; GENE; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; MOLECULAR BIOLOGY; ONCOGENE H RAS; ONCOGENE K RAS; ONCOGENE N RAS; OVARY CANCER; PRIORITY JOURNAL; PROTEIN FAMILY; PROTEIN PROCESSING; PROTEIN STRUCTURE; RAB GENE; REVIEW; SIGNAL TRANSDUCTION;

CELL TRANSFORMATION, NEOPLASTIC; FEMALE; GENES, RAS; HUMANS; MUTATION; NEOPLASM PROTEINS; OVARIAN NEOPLASMS; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; RAB GTP-BINDING PROTEINS; RAS PROTEINS; RHO GTP-BINDING PROTEINS;

EID: 77953664430     PISSN: 09273042     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-0-387-98094-2_11     Document Type: Review

References (80)

1. Colicelli J. Human RAS superfamily proteins and related GTPases. Science STKE. 2004:RE13.
2. Etienne-Manneville S, Hall A. Rho GTPases in cell biology. Nature. 2002;420:629-635.
3. Pfeffer S, Aivazian D. Targeting Rab GTPases to distinct membrane compartments. Nat Rev Mol Cell Biol. 2004;5:886-896.
4. Rocks O, Peyker A, Bastiaens PI. Spatio-temporal segregation of Ras signals: one ship, three anchors, many harbors. Curr Opin Cell Biol. 2006;18:351-357.
5. Quimby BB, Dasso M. The small GTPase Ran: interpreting the signs. Curr Opin Cell Biol. 2003;15:338-344.
6. D'Souza-Schorey C, Chavrier P. ARF proteins: roles in membrane traffic and beyond. Nat Rev Mol Cell Biol. 2006;7:347-358.
7. Biou V, Cherfils J. Structural principles for the multispecificity of small GTP-binding proteins. Biochemistry. 2004;43:6833-6840.
8. Repasky GA, Chenette EJ, Der CJ. Renewing the conspiracy theory debate: does Raf function alone to mediate Ras oncogenesis? Trends Cell Biol. 2004;14:639-647.
9. Bishop AL, Hall A. Rho GTPases and their effector proteins. Biochem J. 2000;348: 241-255.
10. Vetter IR, Wittinghofer A. The guanine nucleotide-binding switch in three dimensions. Science. 2001;294:1299-1304.
11. Herrmann C. Ras-effector interactions: after one decade. Curr Opin Struct Biol. 2003;13:122-129.
12. Bourne HR, Sanders DA, McCormick F. The GTPase superfamily: conserved structure and molecular mechanism. Nature. 1991;349:117-127.
13. Rossman KL, Der CJ, Sondek J. GEF means go: turning on RHO GTPases with guanine nucleotide-exchange factors. Nat Rev Mol Cell Biol. 2005;6:167-180.
14. Schmidt A, Hall A. Guanine nucleotide exchange factors for Rho GTPases: turning on the switch. Genes Dev. 2002;16:1587-1609.
15. Bernards A, Settleman J. GAP control: regulating the regulators of small GTPases. Trends Cell Biol. 2004;14:377-385.
16. Konstantinopoulos PA, Karamouzis MV, Papavassiliou AG. Post-translational modifications and regulation of the RAS superfamily of GTPases as anticancer targets. Nat Rev Drug Discov. 2007;6(7):541-555.
17. Cox AD, Der CJ. Ras family signaling: therapeutic targeting. Cancer Biol Ther. 2002;1: 599-606.
18. DerMardirossian C, Bokoch GM. GDIs: central regulatory molecules in Rho GTPase activation. Trends Cell Biol. 2005;15:356-363.
19. Seabra MC, Wasmeier C. Controlling the location and activation of Rab GTPases. Curr Opin Cell Biol. 2004;16:451-457.
20. Downward J. Targeting RAS signalling pathways in cancer therapy. Nat Rev. 2003;3(1):11-22.
21. Bos JL. Ras oncogenes in human cancer: a review. Cancer Res. 1989;49(17):4682-4689.
22. Shayesteh L, Lu Y, Kuo WL, et al. PIK3CA is implicated as an oncogene in ovarian cancer. Nat Genet. 1999;21(1):99-102.
23. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417(6892):949-954.
24. Schubbert S, Shannon K, Bollag G. Hyperactive Ras in developmental disorders and cancer. Nat Rev. 2007;7(4):295-308.
25. Orsulic S, Li Y, Soslow RA, Vitale-Cross LA, Gutkind JS, Varmus HE. Induction of ovarian cancer by defined multiple genetic changes in a mouse model system. Cancer Cell. 2002;1(1):53-62.
26. Mayr D, Hirschmann A, Lohrs U, Diebold J. KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants. Gynecol Oncol. 2006;103(3):883-887.
27. Bell DA. Origins and molecular pathology of ovarian cancer. Mod Pathol. 2005(Suppl 2):S19-S32.
28. Shih IeM, Kurman RJ. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol. 2004;164(5):1511- 1518.
29. Kurman RJ, Shih IeM. Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications. Int J Gynecol Pathol. 2008;27(2):151-160.
30. Scambia G, Masciullo V, Benedetti Panici P, et al. Prognostic significance of ras/p21 alterations in human ovarian cancer. Br J Cancer. 1997;75(10):1547-1553.
31. Scambia G, Catozzi L, Panici PB, et al. Expression of ras oncogene p21 protein in normal and neoplastic ovarian tissues: correlation with histopathologic features and receptors for estrogen, progesterone, and epidermal growth factor. Am J Obstet Gynecol. 1993;168 (1 Pt 1):71-78.
32. Yaginuma Y, Yamashita K, Kuzumaki N, Fujita M, Shimizu T. Ras oncogene product p21 expression and prognosis of human ovarian tumors. Gynecol Oncol. 1992; 46(1):45-50.
33. Rodenburg CJ, Koelma IA, Nap M, Fleuren GJ. Immunohistochemical detection of the ras oncogene product p21 in advanced ovarian cancer. Lack of correlation with clinical outcome. Arch Pathol Lab Med. 1988;112(2):151-154.
34. Zhou DJ, Gonzalez-Cadavid N, Ahuja H, Battifora H, Moore GE, Cline MJ. A unique pattern of proto-oncogene abnormalities in ovarian adenocarcinomas. Cancer. 1988;62 (8):1573-1586.
35. van Dam PA, Vergote IB, Lowe DG, et al. Expression of c-erbB-2, c-myc, and c-ras oncoproteins, insulin-like growth factor receptor I, and epidermal growth factor receptor in ovarian carcinoma. J Clin Pathol. 1994;47(10):914-919.
36. Cuatrecasas M, Erill N, Musulen E, Costa I, Matias-Guiu X, Prat J. K-ras mutations in nonmucinous ovarian epithelial tumors: a molecular analysis and clinicopathologic study of 144 patients. Cancer. 1998;82(6):1088-1095.
37. Varras MN, Sourvinos G, Diakomanolis E, et al. Detection and clinical correlations of ras gene mutations in human ovarian tumors. Oncology. 1999;56(2):89-96.
38. Sahai E, Marshall CJ. RHO-GTPases and cancer. Nat Rev Cancer. 2002;2:133-142.
39. Burbelo P, Wellstein A, Pestell RG. Altered Rho GTPase signaling pathways in breast cancer cells. Breast Cancer Res Treat. 2004;84(1):43-58.
40. Ridley AJ. Rho GTPases and actin dynamics in membrane protrusions and vesicle trafficking. Trends Cell Biol. 2006;16:522-529.
41. Kleer CG, Griffith KA, Sabel MS, et al. Rho-GTPase is a novel tissue biomarker associated with biologically aggressive carcinomas of the breast. Breast Cancer Res Treat. 2005;93:101-110.
42. Kamai T, Tsujii T, Arai K, et al. Significant association of Rho/ROCK pathway with invasion and metastasis of bladder cancer. Clin Cancer Res. 2003;9:2632-2641.
43. Clark EA, Golub TR, Lander ES, Hynes RO. Genomic analysis of metastasis reveals an essential role for RhoC. Nature. 2000;406(6795):532-535.
44. Fidyk N, Wang JB, Cerione RA. Influencing cellular transformation by modulating the rates of GTP hydrolysis by Cdc42. Biochemistry. 2006;45:7750-7762.
45. Lin R, Cerione RA, Manor D. Specific contributions of the small GTPases Rho, Rac, and Cdc42 to Dbl transformation. J Biol Chem. 1999;274:23633-23641.
46. Horiuchi A, Imai T, Wang C, et al. Up-regulation of small GTPases, RhoA and RhoC, is associated with tumor progression in ovarian carcinoma. Lab Invest. 2003;83(6):861-870.
47. Han Z,XuG, Zhou J, et al. Inhibition ofmotile and invasive properties of ovarian cancer cells by ASODN against Rho-associated protein kinase. Cell Commun Adhes. 2005;12(1-2):59-69.
48. Durkin ME, Ullmannova V, Guan M, Popescu NC. Deleted in liver cancer 3 (DLC-3), a novel Rho GTPase-activating protein, is downregulated in cancer and inhibits tumor cell growth. Oncogene. 2007;6(31):4580-4589.
49. Touchot N, Chardin P, Tavitian A. Four additional members of the ras gene superfamily isolated by an oligonucleotide strategy: molecular cloning of YPT-related cDNAs from a rat brain library. Proc Natl Acad Sci U S A. 1987;84(23):8210-8214.
50. Zerial M, McBride H. Rab proteins as membrane organizers. Nat Rev Mol Cell Biol. 2001;2:107-117.
51. Schwartz SL, Cao C, Pylypenko O, Rak A, Wandinger-Ness A. Rab GTPases at a glance. J Cell Sci. 2007;120(Pt 22):3905-3910.
52. Bucci C, Chiariello M. Signal transduction gRABs attention. Cell Signal. 2006;18(1):1-8.
53. Miaczynska M, Christoforidis S, Giner A, et al. APPL proteins link Rab5 to nuclear signal transduction via an endosomal compartment. Cell. 2004;116:445-456.
54. Miaczynska M, Pelkmans L, Zerial M. Not just a sink: endosomes in control of signal transduction. Curr Opin Cell Biol. 2004;16:400-406.
55. Wu M, Yin G, Zhao X, et al. Human RAB24, interestingly and predominantly distributed in the nuclei of COS-7 cells, is colocalized with cyclophilin A and GABARAP. Int J Mol Med. 2006;17:749-754.
56. Alto NM, Soderling J, Scott JD. Rab32 is an A-kinase anchoring protein and participates in mitochondrial dynamics. J Cell Biol. 2002;158:659-668.
57. Hood DA, Irrcher I, Ljubicic V, Joseph AM. Coordination of metabolic plasticity in skeletal muscle. J Exp Biol. 2006;209:2265-2275.
58. Del Nery E, Miserey-Lenkei S, Falguieres T, et al. Rab6A and Rab6A' GTPases play non-overlapping roles in membrane trafficking. Traffic. 2006;7:394-407.
59. Fan Y, Xin XY, Chen BL, Ma X. Knockdown of RAB25 expression by RNAi inhibits growth of human epithelial ovarian cancer cells in vitro and in vivo. Pathology. 2006;38:561-567.
60. Iida H, Noda M, Kaneko T, Doiguchi M, Mori T. Identification of rab12 as a vesicleassociated small GTPase highly expressed in Sertoli cells of rat testis. Mol Reprod Dev. 2005;71:178-185.
61. Kouranti I, Sachse M, Arouche N, Goud B, Echard A. Rab35 regulates an endocytic recycling pathway essential for the terminal steps of cytokinesis. Curr Biol. 2006; 16:1719-1725.
62. Wang W, Wyckoff JB, Frohlich VC, et al. Single cell behavior in metastatic primary mammary tumors correlated with gene expression patterns revealed by molecular profiling. Cancer Res. 2002;62:6278-6288.
63. Yu X, Prekeris R, Gould GW. Role of endosomal Rab GTPases in cytokinesis. Eur J Cell Biol. 2007;86:25-35.
64. Roach WG, Chavez JA, Miinea CP, Lienhard GE. Substrate specificity and effect on GLUT4 translocation of the Rab GTPase-activating protein Tbc1d1. Biochem J. 2007; 403:353-358.
65. Wang Y, Ng EL, Tang BL. Rab23: what exactly does it traffic? Traffic. 2006;7:746-750.
66. Cheng KW, Lahad JP, Gray JW, Mills GB. Emerging role of RAB GTPases in cancer and human disease. Cancer Res. 2005;65:2516-2519.
67. Chua CE, Tang BL. Alpha-synuclein and Parkinson's disease: the first roadblock. J Cell Mol Med. 2006;10:837-846.
68. Di Pietro SM, Dell'Angelica EC. The cell biology of Hermansky-Pudlak syndrome: recent advances. Traffic. 2005;6:525-533.
69. Inglis PN, Boroevich KA, Leroux MR. Piecing together a ciliome. Trends Genet. 2006;22:491-500.
70. Ménasché G, Pastural E, Feldmann J, et al. Mutations in RAB27A cause Griscelli syndrome associated with haemophagocytic syndrome. Nat Genet. 2000;25(2):173-176.
71. Croizet-Berger K, Daumerie C, Couvreur M, Courtoy PJ, van den Hove MF. The endocytic catalysts, Rab5a and Rab7, are tandem regulators of thyroid hormone production. Proc Natl Acad Sci U S A. 2002;99(12):8277-8282.
72. He H, Dai F, Yu L, et al. Identification and characterization of nine novel human small GTPases showing variable expressions in liver cancer tissues. Gene Expr. 2002;10 (5-6):231-242.
73. Cheng KW, Lahad JP, Kuo WL, et al. The RAB25 small GTPase determines aggressiveness of ovarian and breast cancers. Nat Med. 2004;10(11):1251-1256.
74. Calvo A, Xiao N, Kang J, et al. Alterations in gene expression profiles during prostate cancer progression, functional correlations to tumorigenicity and down-regulation of selenoprotein-P in mouse and human tumors. Cancer Res. 2002;62:5325-5335.
75. Mor O, Nativ O, Stein A, et al. Molecular analysis of transitional cell carcinoma using cDNA microarray. Oncogene. 2003;22:7702-7710.
76. Natrajan R, Williams RD, Hing SN, et al. Array CGH profiling of favourable histology Wilms tumours reveals novel gains and losses associated with relapse. J Pathol. 2006; 210(1):49-58.
77. Caswell PT, Spence HJ, Parsons M, et al. Rab25 associates with alpha5beta1 integrin to promote invasive migration in 3D microenvironments. Dev Cell. 2007;13(4):496-510.
78. Coudert B, Anthoney A, Fiedler W, et al. European Organization for Research and Treatment of Cancer (EORTC). Phase II trial with ISIS 5132 in patients with small-cell (SCLC) and non-small cell (NSCLC) lung cancer.AEuropean Organization for Research and Treatment of Cancer (EORTC) Early Clinical Studies Group report. Eur J Cancer. 2001;37(17):2194-2198.
79. End DW, Smets G, Todd AV, et al. Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro. Cancer Res. 2001;61(1):131-137.
80. Rao S, Cunningham D, de Gramont A, et al. Phase III double-blind placebo-controlled study of farnesyl transferase inhibitor R115777 in patients with refractory advanced colorectal cancer. J Clin Oncol. 2004;22(19):3950-3957.